knowledge -WSS

knowledge

author：Wikipedia 2025-08-11 11:44:02 - browse：7

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

leisure time

WSS

Biotech stock slump in 2023: awaiting the turnaround

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Changes to biosimilar regulatory framework must prioritize patients

The drug industry has found itself all alone in Washington

Amylyx ALS drug fails large clinical trial

FDA panel to weigh approval of NurOwn, controversial ALS drug

leisure time

knowledge

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Biotech stock slump in 2023: awaiting the turnaround

Hollywood unions extend contract negotiations for actors

Intarcia’s device

Malaria cases in Florida and Texas: Here’s what you need to know

Senate HELP committee spars over health care workforce policies

Virginia high school admissions case could be legal follow

Lasker Awards 2023: Winners in biomedical research

What does generative AI mean for health care? We asked experts

Novo Nordisk obesity pill bests Wegovy in early trial

entertainment

Why are Kaiser Permanente staff considering a strike?

Why are Kaiser Permanente staff considering a strike?

Sen. Paul opposes bill to ban Chinese biotechs

Sen. Paul opposes bill to ban Chinese biotechs

Amylyx ALS drug failure raises questions and concerns

STAT Virtual Event: Putting AI to the Test

leisure time

focus

leisure time

hotspot